San Antonio biotech acquires U.K. wound-care company

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare ...

Kiromic founder says Houston biotech’s move to SA nearly a done deal

Houston-based immunotherapy company Kiromic is expected this month to approve moving its headquarters ...


4th Annual SURF 2018

What: San Antonio Military Health System and Universities ResearchForum When: Thursday, June ...

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
San Antonio’s Acelity names new CEO
April 5, 2017

Andrew Eckert, CEO

By Patrick Danner, San Antonio Express-News

San Antonio wound-care company Acelity LP Inc. has appointed R. Andrew Eckert as chief executive and president, replacing Joseph Woody.

Acelity described Eckert as a "seasoned executive" who has headed numerous public and private health-care technology and services companies. He most recently served as CEO of Valence Health in the Chicago area for about 15 months, according to his LinkedIn page.
The company, formerly known as Kinetic Concepts Inc., didn't say why it was replacing Woody.

Acelity is owned by a group led by London-based private equity firm Apax Partners. The San Antonio company was acquired for $6.3 billion in a leveraged buyout in 2011.

Buddy Gumina, Acelity's chairman, said it has hired a proven leader to take the helm as it embarks on "a promising new phase in the transformation of Acelity." Gumina said the company is concentrating on developing and expanding its portfolio of advanced-wound therapies."

Eckert said he looks forward to the challenge of navigating Acelity during "the complex evolution of healthcare delivery in markets around the world," according to the statement released by the company. Acelity has about 4,800 employees, 1,500 of which are based in San Antonio.

"We have an important opportunity to realize growth by embracing the shift to value-based care and delivering to patients and customers innovative products and therapies that address the burdens of treating chronic and acute wounds," Eckert said.

Eckert's appointment comes just two months after Acelity sold LifeCell Corp., a regenerative medicine business, to pharmaceutical giant Allergan for $2.9 billion. The sale took place after Acelity ditched its plans for an initial public offering in December "in light of current market conditions."

Woody was appointed Acelity's CEO and president in early 2012, two months after joining the company as a division head. He replaced Catherine Burzick, who left after the leveraged buyout.

Acelity, in its statement, credited Woody with integrating Kinetic Concepts, LifeCell and wound-care development company Systagenix, which was acquired for $485 million in 2013, "to create a global leader in medical device and technology."

Eckert has served as CEO of Colorado-based TriZetto Corp., a provider of health-care information technology, which was acquired by New Jersey-based Cognizant Technology Solutions Corp. in 2014. Ironically, Apax Partners and other investors agreed to sell their stakes in TriZetto for $2.7 billion in 2014.

Eckert currently serves on the boards of Varian Medical Systems of Palo Alto, California and Becton, Dickinson and Co. of New Jersey.


Stay informed. Subscribe to BioMed SA news alerts.